Beam (NASDAQ: BEAM) insider schedules Rule 144 sale after prior stock sales

Rhea-AI Filing Summary

Beam Therapeutics insider plans additional stock sale under Rule 144. A holder intends to sell 1,371 shares of Beam common stock through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of 46,614.00. The approximate sale date is 01/22/2026, and 101,474,944 shares of common stock were outstanding at the time referenced.

The shares to be sold were acquired as restricted stock from the issuer on three dates in 2024, totaling 1,371 shares. Over the past three months, the same seller, Christine Bellon, has already sold 18,629 shares of common stock for gross proceeds of 644,830.68 and 1,254 shares for 33,978.85. The form includes a representation that the seller is not aware of undisclosed material adverse information about Beam’s operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1371	46614.00	101474944	01/22/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/31/2024	Restricted Stock	ISSUER			310	12/31/2024	Not Applicable
Common	03/31/2024	Restricted Stock	ISSUER			196	03/31/2024	Not Applicable
Common	09/30/2024	Restricted Stock	ISSUER			865	09/30/2024	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
CHRISTINE BELLON 238 Main Street Cambridge MA 02142	Common	01/15/2026	18629	644830.68
CHRISTINE BELLON 238 Main Street Cambridge MA 02142	Common	01/02/2026	1254	33978.85

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Beam Therapeutics (BEAM) Form 144 show about recent insider sales?

The Form 144 shows that insider Christine Bellon has recently sold Beam common stock and plans an additional sale. In the past three months, she sold 18,629 shares for gross proceeds of 644,830.68 and 1,254 shares for 33,978.85, and now plans to sell 1,371 more shares.

How many Beam Therapeutics (BEAM) shares are proposed to be sold under this Form 144?

The notice covers a proposed sale of 1,371 shares of Beam Therapeutics common stock. These shares have an aggregate market value of 46,614.00 based on the figures in the form.

How were the Beam Therapeutics (BEAM) shares being sold under Form 144 acquired?

The 1,371 Beam common shares to be sold were acquired as restricted stock from the issuer. They were granted in three tranches on 03/31/2024, 09/30/2024, and 12/31/2024, in amounts of 196, 865, and 310 shares, respectively.

When is the planned sale date and on which exchange will Beam Therapeutics (BEAM) shares be sold?

The approximate date of sale listed is 01/22/2026. The shares are expected to be sold on the NASDAQ exchange through Morgan Stanley Smith Barney LLC, Executive Financial Services.

How many Beam Therapeutics (BEAM) shares were outstanding in this Form 144?

The Form 144 states that 101,474,944 shares of Beam Therapeutics common stock were outstanding as of the reference point in the filing; this is a baseline figure and not the amount being sold.

What representation does the seller make in this Beam Therapeutics (BEAM) Form 144?

By signing the notice, the seller represents that they do not know of any material adverse information about Beam’s current or prospective operations that has not been publicly disclosed, as required under Rule 144.